Overactive Bladder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major overactive bladder markets reached a value of US$ 2.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.3 Billion by 2034, exhibiting a growth rate (CAGR) of 2.42% during 2024-2034.
The overactive bladder market has been comprehensively analyzed in IMARC's new report titled "Overactive Bladder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Overactive bladder (OAB) is a medical condition that is characterized by a sudden, uncontrollable urge to urinate. The common symptoms associated with the ailment include a difficult-to-control need to urinate, urinary incontinence, frequent urination, nocturia, etc. Individuals suffering from OAB may also experience disrupted sleep, fatigue, depression, skin problems, infections, etc. This disease can limit a person's work and social interactions, causing a negative impact on their life. The diagnosis of OAB is made by evaluating the medical history, physical exam, and clinical features. Diagnostic tests may include a urine test to rule out infection, a post-void residual (PVR) examination to measure how much urine is left in the bladder after urination, and urodynamic testing to evaluate bladder function. In some cases, various imaging tests, such as an ultrasound or CT scan, may be used to look for structural abnormalities in the bladder or urinary tract. Numerous other diagnostic procedures, including urine workups, bladder ultrasounds, cystoscopies, etc., are also utilized to confirm a diagnosis among patients. Additionally, healthcare professionals may recommend maintaining a bladder diary to better understand the body processes and determine other risk factors that worsen the symptoms.
The increasing prevalence of urinary tract infections, which cause overactivity of the detrusor urinae muscle and involuntary bladder contractions, is primarily driving the overactive bladder market. Furthermore, the rising cases of aging-related cognitive decline that make it challenging for the bladder to comprehend the signals it gets from the brain are also bolstering the market growth. Apart from this, the inflating utilization of effective medications for treating the condition, including antimuscarinics and beta-3 agonists, which can help relax the bladder muscle as well as increase urine retention and emptying capacity, is acting as another significant growth-inducing factor. Moreover, the escalating application of neuromodulation therapy to improve OAB symptoms is further creating a positive outlook for the market. This approach stimulates electrical pulses between the brain neurons and the bladder to ensure normal bladder function. Additionally, the emerging popularity of conservative measures, including lifestyle modification and pelvic floor physical therapy, for managing the condition since they can lower the risk of disease progression, ease symptoms, and improve the quality of life in patients is expected to drive the overactive bladder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the overactive bladder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for overactive bladder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the overactive bladder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the overactive bladder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the overactive bladder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current overactive bladder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the overactive bladder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the overactive bladder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the overactive bladder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of overactive bladder across the seven major markets?
What is the number of prevalent cases (2018-2034) of overactive bladder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of overactive bladder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with overactive bladder across the seven major markets?
What is the size of the overactive bladder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of overactive bladder?
What will be the growth rate of patients across the seven major markets?
Overactive Bladder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for overactive bladder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the overactive bladder market?
What are the key regulatory events related to the overactive bladder market?
What is the structure of clinical trial landscape by status related to the overactive bladder market?
What is the structure of clinical trial landscape by phase related to the overactive bladder market?
What is the structure of clinical trial landscape by route of administration related to the overactive bladder market?
The overactive bladder market has been comprehensively analyzed in IMARC's new report titled "Overactive Bladder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Overactive bladder (OAB) is a medical condition that is characterized by a sudden, uncontrollable urge to urinate. The common symptoms associated with the ailment include a difficult-to-control need to urinate, urinary incontinence, frequent urination, nocturia, etc. Individuals suffering from OAB may also experience disrupted sleep, fatigue, depression, skin problems, infections, etc. This disease can limit a person's work and social interactions, causing a negative impact on their life. The diagnosis of OAB is made by evaluating the medical history, physical exam, and clinical features. Diagnostic tests may include a urine test to rule out infection, a post-void residual (PVR) examination to measure how much urine is left in the bladder after urination, and urodynamic testing to evaluate bladder function. In some cases, various imaging tests, such as an ultrasound or CT scan, may be used to look for structural abnormalities in the bladder or urinary tract. Numerous other diagnostic procedures, including urine workups, bladder ultrasounds, cystoscopies, etc., are also utilized to confirm a diagnosis among patients. Additionally, healthcare professionals may recommend maintaining a bladder diary to better understand the body processes and determine other risk factors that worsen the symptoms.
The increasing prevalence of urinary tract infections, which cause overactivity of the detrusor urinae muscle and involuntary bladder contractions, is primarily driving the overactive bladder market. Furthermore, the rising cases of aging-related cognitive decline that make it challenging for the bladder to comprehend the signals it gets from the brain are also bolstering the market growth. Apart from this, the inflating utilization of effective medications for treating the condition, including antimuscarinics and beta-3 agonists, which can help relax the bladder muscle as well as increase urine retention and emptying capacity, is acting as another significant growth-inducing factor. Moreover, the escalating application of neuromodulation therapy to improve OAB symptoms is further creating a positive outlook for the market. This approach stimulates electrical pulses between the brain neurons and the bladder to ensure normal bladder function. Additionally, the emerging popularity of conservative measures, including lifestyle modification and pelvic floor physical therapy, for managing the condition since they can lower the risk of disease progression, ease symptoms, and improve the quality of life in patients is expected to drive the overactive bladder market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the overactive bladder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for overactive bladder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the overactive bladder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the overactive bladder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the overactive bladder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current overactive bladder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the overactive bladder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the overactive bladder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the overactive bladder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of overactive bladder across the seven major markets?
What is the number of prevalent cases (2018-2034) of overactive bladder by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of overactive bladder by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with overactive bladder across the seven major markets?
What is the size of the overactive bladder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of overactive bladder?
What will be the growth rate of patients across the seven major markets?
Overactive Bladder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for overactive bladder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the overactive bladder market?
What are the key regulatory events related to the overactive bladder market?
What is the structure of clinical trial landscape by status related to the overactive bladder market?
What is the structure of clinical trial landscape by phase related to the overactive bladder market?
What is the structure of clinical trial landscape by route of administration related to the overactive bladder market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OVERACTIVE BLADDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OVERACTIVE BLADDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OVERACTIVE BLADDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 OVERACTIVE BLADDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OVERACTIVE BLADDER - UNMET NEEDS
10 OVERACTIVE BLADDER - KEY ENDPOINTS OF TREATMENT
11 OVERACTIVE BLADDER - MARKETED PRODUCTS
11.1 List of Overactive Bladder Marketed Drugs Across the Top 7 Markets
11.1.1 Sanctura (Trospium chloride) - AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Toviaz (Fesoterodine) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gelnique (Oxybutynin transdermal) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Myrbetriq (Mirabegron) - Astellas Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Gemtesa (Vibegron) - Kyorin Pharmaceutical/Urovant Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OVERACTIVE BLADDER - PIPELINE DRUGS
12.1 List of Overactive Bladder Pipeline Drugs Across the Top 7 Markets
12.1.1 BAY1817080 - Bayer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 URO-902 - Urovant Sciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TAC-302 - Taiho Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OVERACTIVE BLADDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OVERACTIVE BLADDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OVERACTIVE BLADDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Overactive Bladder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Overactive Bladder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Overactive Bladder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Overactive Bladder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Overactive Bladder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Overactive Bladder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Overactive Bladder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Overactive Bladder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Overactive Bladder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Overactive Bladder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Overactive Bladder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Overactive Bladder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Overactive Bladder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Overactive Bladder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Overactive Bladder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Overactive Bladder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Overactive Bladder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Overactive Bladder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Overactive Bladder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Overactive Bladder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Overactive Bladder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Overactive Bladder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Overactive Bladder - Access and Reimbursement Overview
16 OVERACTIVE BLADDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OVERACTIVE BLADDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OVERACTIVE BLADDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OVERACTIVE BLADDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OVERACTIVE BLADDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OVERACTIVE BLADDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 OVERACTIVE BLADDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OVERACTIVE BLADDER - UNMET NEEDS
10 OVERACTIVE BLADDER - KEY ENDPOINTS OF TREATMENT
11 OVERACTIVE BLADDER - MARKETED PRODUCTS
11.1 List of Overactive Bladder Marketed Drugs Across the Top 7 Markets
11.1.1 Sanctura (Trospium chloride) - AbbVie
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Toviaz (Fesoterodine) - Pfizer
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Gelnique (Oxybutynin transdermal) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Myrbetriq (Mirabegron) - Astellas Pharma
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Gemtesa (Vibegron) - Kyorin Pharmaceutical/Urovant Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OVERACTIVE BLADDER - PIPELINE DRUGS
12.1 List of Overactive Bladder Pipeline Drugs Across the Top 7 Markets
12.1.1 BAY1817080 - Bayer
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 URO-902 - Urovant Sciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TAC-302 - Taiho Pharmaceutical
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OVERACTIVE BLADDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OVERACTIVE BLADDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OVERACTIVE BLADDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Overactive Bladder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Overactive Bladder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Overactive Bladder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Overactive Bladder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Overactive Bladder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Overactive Bladder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Overactive Bladder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Overactive Bladder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Overactive Bladder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Overactive Bladder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Overactive Bladder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Overactive Bladder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Overactive Bladder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Overactive Bladder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Overactive Bladder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Overactive Bladder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Overactive Bladder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Overactive Bladder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Overactive Bladder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Overactive Bladder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Overactive Bladder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Overactive Bladder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Overactive Bladder - Access and Reimbursement Overview
16 OVERACTIVE BLADDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OVERACTIVE BLADDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OVERACTIVE BLADDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
